GINAL LAPS ROC'D PCT/PTO 05 MAY 2008

d for use through 3/31/2007. OMB 0651-0021 U.S. Patent and Tracomark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** ATTTORNEY'S DOCKET NUMBER

Le A 36 437

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/534,138

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP03/011880 10/25/03 (Oct 25, 2003) 11/8/02 (Nov 8, 2002) TITLE OF INVENTION SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES APPLICANT(S) FOR DO/EO/US WUNBERG, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13 X A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.

Other items or information: 1. Return Receipt Postcard 2. Copy of Notification of Missing Requirements

3. Petition for Extension of Time

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

A second copy of the published International Application under 35 U.S.C. 154(d)(4).

20.

Page 1 of 2 Date of Deposit: 5/2/06

PICT PCT/PTO 05 MAY 2006

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		/ UFK 1.5)	INTERNATIONAL APPLICATION NO.			ATTORNET S DOCKET NUMBER		
	10/534,138			PCT/EP03/011880			Le A 36 437		
	21. The following fees are submitted:						\$		
	a) Basic national fee								
							\$		
							\$		
							\$		
	Additional fee	for specification and dr	g sequence						
	additional:50	puter program listing file sheets of paper or fract	reacn						
	Total Sheets					RATE			
	- 100 =	/50 =				× \$250.00	\$ 0.00		
	Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$ 130.00		
	CLAIMS	NUMBER FIL	.ED	NUMBER EXTRA		RATE	\$		
	Total claims	14	- 20 =	0	х	\$50.00	\$		
	Independent claim		- 3 =	0	х	\$200.00	\$		
	MULTIPLE DEPEN	NDENT CLAIM(S) (if ap	plicable)	0	+	\$360.00	\$		
	TOTAL OF ABOVE CALCULATIONS =						\$ 130.00		
							\$		
	SUBTOTAL ≃						\$ 130.00		
	Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$		
	TOTAL NATIONAL FEE =						\$ 130.00		
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$		
05/12/2006°L	ANDGRA 0000007	1 133372 1053413	138 TOTAL FEES ENCLOSED =				\$ 130.00		
01 FC:1617	130.00 DA						Amount to be refunded:	\$	
	·						Amount to be charged:	_{\$} 130.00	
	a. A check	in the amount of \$		to cover the abo	ve foor	ic and seed	9		
	b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 130.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-3372. A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) mand granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO: Customer No. 35969							A 11.	,	
	Jeffrey M. Greenman Bayer Pharmaceuticals Corporation SIGNATUR AND Margan Language Appears A						ra A. Shinii		
	400 Morgan West Haven,					Arbara A. S	ominei		
	29,862								
							ON NUMBER		

FORM PTO-1390 (REV. 12-2004)

Page 2 of 2

PRIORITY DATE

11/08/2002





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY, DOCKET NO.
10/534,138	Tobias Wunberg	Le A 36 437
		INTERNATIONAL APPLICATION NO.
		PCT/EP03/11880

35969 JEFFREY M. GREENMAN BAYER PHARMACEUTICALS CORPORATION 400 MORGAN LANE WEST HAVEN, CT 06516

CONFIRMATION NO. 8469 371 FORMALITIES LETTER

OC000000017359302

I.A. FILING DATE

10/25/2003

Date Mailed: 11/02/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 05/06/2005
- English Translation of the IA filed on 05/06/2005
- Copy of the International Search Report filed on 05/06/2005
- Copy of IPE Report filed on 05/06/2005
- Request for Immediate Examination filed on 05/06/2005
- U.S. Basic National Fees filed on 05/06/2005
- Priority Documents filed on 05/06/2005

01/48/2005 LLINBORN 60001025 422272 10524138

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of \$360 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath
 or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the
 missing items identified in this letter.

SUMMARY OF FEES DUE:



Total additional fees required for this application is \$490 for a Large Entity:

- \$130 Surcharge.
- Total additional claim fee(s) for this application is \$ 360
 - \$360 for multiple dependent claim surchare.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/534,138	PCT/EP03/11880	Le A 36 437

FORM PCT/DO/EO/905 (371 Formalities Notice)